Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: Neurotoxic and therapeutic implications

被引:75
作者
Fleckenstein, Annette E. [1 ]
Volz, Trent J. [1 ]
Hanson, Glen R. [1 ]
机构
[1] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA
关键词
VMAT-2; Dopamine transporter; Monoamine transporters; Methylphenidate; Methamphetamine; Dopamine receptors; Drug abuse; Parkinson's disease; Cocaine; Dopamine neurotoxicity; Lobeline; Monoamine vesicles; METHAMPHETAMINE-INDUCED CHANGES; TYROSINE-HYDROXYLASE ACTIVITY; DOPAMINE UPTAKE; STRIATAL DOPAMINE; PARKINSONS-DISEASE; RAT-BRAIN; NEUROTRANSMITTER RELEASE; RADICAL FORMATION; OXIDATIVE STRESS; METHYLPHENIDATE;
D O I
10.1016/j.neuropharm.2008.07.002
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The vesicular monoamine transporter-2 (VMAT-2) is an important regulator of intraneuronal monoamine concentrations and disposition as this protein sequesters critical cytoplasmic monoaminergic transmitters and contributes to their Subsequent exocytotic release. This review primarily discusses the impact of psychoactive drugs (including those with abuse potential) on dopamine (DA)-related VMAT-2 and its function. In particular, the different responses by DA-related VMAT-2 and associated vesicles to plasmalemmal uptake blockers like methylphenidate and releasers like methamphetamine are presented. Recent preclinical findings suggest that vesicular transporter systems are highly regulatable, both by changes in localization as well as alterations in the kinetics of the VMAT-2 protein. The capacity for such shifts in VMAT-2 functions Suggests the presence of physiological regulation that likely influences the activity of DA systems. In addition, these findings may contribute to our understanding of the pathogenesis of a variety of DA-related disorders such as substance abuse and Parkinson's disease and also Suggest new therapeutic targets for treating Such diseases. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:133 / 138
页数:6
相关论文
共 61 条
[1]   Methamphetamine rapidly decreases vesicular dopamine uptake [J].
Brown, JM ;
Hanson, GR ;
Fleckenstein, AE .
JOURNAL OF NEUROCHEMISTRY, 2000, 74 (05) :2221-2223
[2]   A single methamphetamine administration rapidly decreases vesicular dopamine uptake [J].
Brown, JM ;
Riddle, EL ;
Sandoval, V ;
Weston, RK ;
Hanson, JE ;
Crosby, MJ ;
Ugarte, YV ;
Gibb, JW ;
Hanson, GR ;
Fleckenstein, AE .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (02) :497-501
[3]  
Brown JM, 2001, J PHARMACOL EXP THER, V298, P1150
[4]  
Brown JM, 2001, J PHARMACOL EXP THER, V296, P762
[5]  
CHU PW, EUR J PHARM IN PRESS
[6]   METHAMPHETAMINE NEUROTOXICITY INVOLVES VACUOLATION OF ENDOCYTIC ORGANELLES AND DOPAMINE-DEPENDENT INTRACELLULAR OXIDATIVE STRESS [J].
CUBELLS, JF ;
RAYPORT, S ;
RAJENDRAN, G ;
SULZER, D .
JOURNAL OF NEUROSCIENCE, 1994, 14 (04) :2260-2271
[7]   STRIATAL SUBREGIONS ARE DIFFERENTIALLY VULNERABLE TO THE NEUROTOXIC EFFECTS OF METHAMPHETAMINE [J].
EISCH, AJ ;
GAFFNEY, M ;
WEIHMULLER, FB ;
ODELL, SJ ;
MARSHALL, JF .
BRAIN RESEARCH, 1992, 598 (1-2) :321-326
[8]   A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine [J].
Eyerman, David J. ;
Yamamoto, Bryan K. .
JOURNAL OF NEUROCHEMISTRY, 2007, 103 (03) :1219-1227
[9]   Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum [J].
Eyerman, DJ ;
Yamamoto, BK .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 312 (01) :160-169
[10]  
Fleckenstein AE, 1997, J PHARMACOL EXP THER, V283, P281